<table>
<thead>
<tr>
<th>Einstein Reference Number</th>
<th>Title of Patent Application</th>
<th>Abstract</th>
<th>Senior Einstein Investigator</th>
<th>Link to Non-Provisional Patent Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-769</td>
<td>Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith</td>
<td>The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875.</td>
<td>Ian M Willis</td>
<td>US 13/298,370</td>
</tr>
<tr>
<td>C-815</td>
<td>Use of oxytocin or oxytocin analogues to treat obesity and diabetes</td>
<td>Methods and compositions for treating obesity or an obesity comorbidity in a subject are provided, employing an inhibitor of synaptotagmin-4 or an amount of oxytocin or an analogue thereof. Methods and compositions for effecting weight gain in a subject are also provided employing synaptotagmin-4, or an analogue of synaptotagmin-4, or an oxytocin antagonist.</td>
<td>Dongsheng Cai</td>
<td>PCT/US12/020404</td>
</tr>
<tr>
<td>C-827</td>
<td>MIR27B is a novel target for treatment of liver fibrosis</td>
<td>Methods are provided for treating fibrosis of a tissue, including fibrosis of the liver, using combinations of antagonirs and/or locked nucleic acids. Compositions therefor are also provided.</td>
<td>Leslie E. Rogler</td>
<td>13/707,055</td>
</tr>
<tr>
<td>C-908</td>
<td>Neural stem cell therapy for obesity and diabetes</td>
<td>Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) IκB kinase β (IKKβ) activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) or (ii) Notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity.</td>
<td>Dongsheng Cai</td>
<td>PCT/US2013/022661</td>
</tr>
<tr>
<td>C-918</td>
<td>Generation of hepatocytes from pluripotent stem cells</td>
<td>Methods are provided for producing differentiated cells from stem cells, including producing hepatocytes. Compositions thereof are also provided, as are methods of treating a liver disorder.</td>
<td>Sanjeev Gupta</td>
<td>PCT/US2013/48113</td>
</tr>
</tbody>
</table>